Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
Top Cited Papers
Open Access
- 31 August 2021
- Vol. 76 (9), 907-919
- https://doi.org/10.1136/thoraxjnl-2020-215266
Abstract
Background There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies exploring the therapeutic role of immunomodulation. Through systematic review and meta-analysis, we assess the effectiveness of specific interleukin inhibitors for the treatment of COVID-19. Methods Electronic databases were searched on 7 January 2021 to identify studies of immunomodulatory agents (anakinra, sarilumab, siltuximab and tocilizumab) for the treatment of COVID-19. The primary outcomes were severity on an Ordinal Scale measured at day 15 from intervention and days to hospital discharge. Key secondary endpoints included overall mortality. Results 71 studies totalling 22 058 patients were included, 6 were randomised trials. Most studies explored outcomes in patients who received tocilizumab (60/71). In prospective studies, tocilizumab was associated with improved unadjusted survival (risk ratio 0.83, 95% CI 0.72 to 0.96, I-2=0.0%), but conclusive benefit was not demonstrated for other outcomes. In retrospective studies, tocilizumab was associated with less severe outcomes on an Ordinal Scale (generalised OR 1.34, 95% CI 1.10 to 1.64, I-2=98%) and adjusted mortality risk (HR 0.52, 95% CI 0.41 to 0.66, I-2=76.6%). The mean difference in duration of hospitalisation was 0.36 days (95% CI -0.07 to 0.80, I-2=93.8%). There was substantial heterogeneity in retrospective studies, and estimates should be interpreted cautiously. Other immunomodulatory agents showed similar effects to tocilizumab, but insufficient data precluded meta-analysis by agent. Conclusion Tocilizumab was associated with a lower relative risk of mortality in prospective studies, but effects were inconclusive for other outcomes. Current evidence for the efficacy of anakinra, siltuximab or sarilumab in COVID-19 is insufficient, with further studies urgently needed for conclusive findings. PROSPERO registration number CRD42020176375.Funding Information
- National Institute for Health Research (Nottingham Biomedical Research Centre. RGJ is supp)
This publication has 92 references indexed in Scilit:
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, ChinaThe Lancet, 2020
- Estimating the sample mean and standard deviation from commonly reported quantiles in meta-analysisStatistical Methods in Medical Research, 2020
- The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — The latest 2019 novel coronavirus outbreak in Wuhan, ChinaInternational Journal of Infectious Diseases, 2020
- Use of the GRADE approach in systematic reviews and guidelinesBritish Journal of Anaesthesia, 2019
- RoB 2: a revised tool for assessing risk of bias in randomised trialsBMJ, 2019
- MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profileCytokine, 2018
- An Improved Method for Simple, Assumption-Free Ordinal Analysis of the Modified Rankin Scale Using Generalized Odds RatiosInternational Journal of Stroke, 2014
- Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or treated with immunomodulatory agentsMediterranean Journal of Hematology and Infectious Diseases, 2010
- Plasma inflammatory cytokines and chemokines in severe acute respiratory syndromeClinical and Experimental Immunology, 2004